Citryll BV is a private pharmaceutical company based in Oss, the Netherlands that is dedicated to the development and commercialization of therapeutics that target NETosis and NETs. Target diseases include SLE, RA, vasculitis, cancer and fibrosis.
Total raised: $127.56M
Founded date: 2015
Investors 3
| Date | Name | Website |
| 18.08.2021 | BioGenerat... | biogenerat... |
| - | Curie Capi... | curiecapit... |
| 19.05.2025 | Forbion | forbion.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.12.2024 | Series B | $89.84M | - |
| 02.07.2020 | - | $20.79M | - |
| 03.07.2019 | Series A | $16.93M | - |
Mentions in press and media 14
| Date | Title | Description |
| 30.07.2025 | NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025 | -- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CE... |
| 25.07.2025 | Citryll Announces Formation Of Scientific Advisory Board | Board comprises world-renowned experts in biology, immunology and pathology. Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Ne... |
| 12.06.2025 | The growth and opportunities of the Netherlands' tech ecosystem | Dutch tech companies raised over €3.7 billion in 2024, accounting for about 5 per cent of the total capital raised in the European tech ecosystem, according to Tech.eu's European Tech 2024: The Big Picture report. This positions the Netherl... |
| 10.12.2024 | Citryll's €85 Million Boost: A New Dawn for Inflammatory Disease Treatment | In the world of biotech, funding is the lifeblood. Recently, Dutch startup Citryll secured a significant €85 million in Series B funding. This financial windfall is not just a number; it represents hope for countless patients battling immun... |
| 09.12.2024 | Citryll Raises Eur 85 Million Series B to Advance Novel Net-Targeting Therapy for Immune-Mediated Inflammatory Disorders | - Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture Fund - Lead first-in-class product candidate, monoclonal antibody CIT-013, to be advanced into two Phase 2a studies Oss, Netherlands – 09 Dece... |
| 09.12.2024 | Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders | CITRYLL RAISES EUR 85 MILLION SERIES B TO ADVANCE NOVEL NET-TARGETING THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERS Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture Fund Lead first-in-clas... |
| 09.12.2024 | Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders | CITRYLL RAISES EUR 85 MILLION SERIES B TO ADVANCE NOVEL NET-TARGETING THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERS Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture Fund Lead first-in-clas... |
| 09.12.2024 | Oss-based Citryll secures €85 million Series B funding to advance NET-targeting therapy | Dutch startup Citryll, a biotech innovator in immune-mediated inflammatory diseases, has raised €85 million in a Series B funding round. The financing was co-led by Johnson & Johnson Innovation (through its corporate venture capital org... |
| 09.12.2024 | Citryll Raises EUR 85M in Series B Funding | Citryll, an Oss, The Netherlands-based biotech company developing a new approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), raised €85M in Series B funding. The round was led by Joh... |
| 02.07.2020 | Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps | OSS, Netherlands-Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration... |
Show more